Alimentary Pharmacology & Therapeutics

Article	Citations
	168
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still out. Authors' Reply	125
AP&T: Editors' Declarations of Interest	103
Issue Information	103
Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification	85
Review: Human Intestinal Barrier—Optimal Measurement and Effects of Diet in the Absence of Overt Inflammation or Ulceration	82
CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy	79
Issue Information	74
	71
Letter: Positivity of High‐Sensitivity HBsAg Test Was Significantly Associated With Poor Prognosis in Patients With Non‐HBV‐Related HCC	70
Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis‐related hospitalisations in the US	67
Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease	67
Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis	65
Editorial: dietary interventions to understand and treat primary sclerosing cholangitis—is gluten‐free diet a starting point?	64
Bradycardia and Other Arrhythmias in Patients With Hepatorenal Syndrome‐Acute Kidney Injury Following Terlipressin Treatment: A Pooled Analysis of Three North American Phase III Clinical St	64
Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease	62
Letter: Real‐Life Evaluation of Effectiveness of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease Emphasises Importance of Appropriate Patient Selection and Centre Expertise—Authors' Rep	62
Network Meta‐Analysis: Comparative Efficacy of Biologics and Small Molecules in the Induction and Maintenance of Remission in Crohn's Disease	62
Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis	61
Meta‐Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea	60
No value of non‐selective beta‐blockers after TIPS‐insertion	57
Longitudinal changes in renal function in patients with chronic hepatitis B on antiviral treatment	57
Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non‐Cirrhotic Patients	56
Gut‐brain axis dysfunction underlies FODMAP‐induced symptom generation in irritable bowel syndrome	54
Colorectal cancer in elderly‐onset inflammatory bowel disease: a 1969–2017 Scandinavian register‐based cohort study	53

Editorial: clinical outcomes in lean NAFLD – the devil is in the details. Authors' reply	50
Cost‐effectiveness of an adjuvanted recombinant zoster vaccine in adults with inflammatory bowel disease	50
Editorial: Will MRI‐PDFF become the new standard for steatosis assessment in NAFLD? Authors' reply	49
	49
Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?	49
Systematic Review: The Relationship Between the Faecal Microbiome and Colorectal Neoplasia in Shotgun Metagenomic Studies	48
Clinical Trial: Effect of Abdominal Vibration Combined With Walking Exercise Programme on Bowel Preparation in Older Patients With Constipation	48
Schizophrenia and risk of new‐onset inflammatory bowel disease: a nationwide longitudinal study	48
Letter: time to consider Pneumocystis jirovecii pneumonia prophylaxis in treatment of autoimmune hepatitis	46
Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis	46
	44
Issue Information	44
Editorial: The future of managing drug induced liver injury	43
Letter: Allostatic load—A potential key in the development of inflammatory bowel disease	43
Letter: Elderly onset inflammatory bowel disease—Treat to target approach is still warranted	42
Editorial: tradipitant has promise for treating gastroparesis but leaves gastric function alone—authors’ reply	42
Positivity of high‐sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non‐HBV‐related HCC	42
Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply	42
Editorial: switching to tenofovir alafenamide monotherapy is effective and safe for other nucleos(t)ide analogues‐treated patients with chronic hepatitis B	42
Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply	41
Editorial: ustekinumab during pregnancy ‐ reassuring but still not enough	41
Editorial: biomarkers for alcohol‐related liver fibrosis—almost there?	40
Letter: ductular reaction is a risk factor for prognosis of chronic hepatitis B complicated with non‐alcoholic fatty liver disease	40
Editorial: Plants against animals	40
Editorial: risk of pneumonia in IBD—reading between the lines!	40
Letter: Ozanimod and latent tuberculosis	38
Letter: Critical appraisal of biologic therapy in early ulcerative colitis management—Addressing study limitations and the role of psychological resilience—Authors' reply	38
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet? Authors' reply	38
Editorial: Advanced glycation end products ‐ a dietary culprit for IBD in the genetically susceptible?	38
Editorial: concurrence of coeliac disease with inflammatory bowel disease – is big data the final arbiter? Authors' reply	38
Letter: practical considerations for nonselective beta‐blocker therapy in portal hypertension	38
Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply	37
Editorial: Assessing advanced fibrosis in metabolic‐associated steatotic liver disease—TheMAFLDfibrosis score	37
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis	37
Editorial: Can we predict or not predict response to hypnotherapy? That is the question	37
Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients	36
Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy	36
First in human randomised trial of J2H‐1702: A novel 11β‐hydroxysteroid dehydrogenase type 1 inhibitor for non‐alcoholic steatohepatitis treatment	36
Diagnostic Accuracy of an Add‐On, Blood‐Based Screening Test for Colorectal Cancer in Two Established Screening Programmes	36
Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?	35
Liver resection versus microwave ablation for hepatocellular carcinoma in ideal candidates for ablation per Barcelona Clinic Liver Cancer staging: a propensity score matching and inverse probability o	35
Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis	35
Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials	34
Review article: Emerging insights into the epidemiology, pathophysiology, diagnostic and therapeutic aspects of eosinophilic oesophagitis and other eosinophilic gastrointestinal diseases	34
Development of a model to identify patients who do not need oesophageal biopsies when eosinophilic oesophagitis is suspected	34
Editorial: Implementing Risk Assessment Tools for MetALD in Clinical Practice—Authors' Reply	34
Prevalence and clinical characteristics of patients with metabolic dysfunction‐associated fatty liver disease with hepatitis C virus infection—a population‐based study	34
Issue Information	33
	33
	33

	33
Editorial: Feeling better about NASH—Authors' reply	33
Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply	33
Letter: Baveno‐VI criteria to exclude large varices in patients with hepatocellular carcinoma—What have we learned?	32
Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply	32
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism	31
Editorial: reducing false alarms with oesophagogastric junction outflow obstruction	31
Editorial: Crystalising the burden of steatotic liver disease—Authors' reply	31
Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply	31
Letter: The importance of histological assessment—a further stride inSTRIDE. Authors' reply	30
Editorial: food insecurity, diet quality, racial and ethnic disparities in non‐alcoholic fatty liver disease	30
Editorial: changes of health‐related quality of life associated with hepatic disease severity and its improvement after treatment in NAFLD—authorsʼ reply	30
Editorial: testing for Epstein Barr virus and treating autoimmune hepatitis—still a long way to go! Authors' reply	30
Editorial: time to eat? Skipping breakfast in metabolic‐associated fatty liver disease	30
Letter: chronic HDV infection—is ignorance bliss? Authors' reply	30
Letter: the value of quality liver biopsy before initiation of corticosteroids for severe alcoholic hepatitis	29
Letter: Are we forgetting the importance of steatosis in steatotic liver disease? Authors' reply	29
Letter: association between COVID‐19 and inflammatory bowel disease	29
Trends in risk factor control and treatment among patients with non‐alcoholic fatty liver disease and type 2 diabetes between 2000 and 2020: A territory‐wide study	28
Faecal incontinence: Retentive, non‐retentive and when to suspect organic pathology	28
Letter: diet‐responsive or just diet‐adherent in eosinophilic oesophagitis. Where is the dietitian?	28
Letter: Irritable bowel syndrome and antibiotics—Authors' reply	28
Letter: Role of Helicobacter pylori and metabolic syndrome‐related insulin resistance and lipotoxicity in the pathogenesis of MAFLD and MASH—Authors’ reply	28
Letter: hereditary role in non‐alcoholic fatty liver disease	28
Letter: the hidden reasons of long‐term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication	27
Editorial: Negative impact of diabetes mellitus and obesity on the prognosis of patients with chronic liver disease—Authors' reply	27
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients	27
Letter: Association between chronic kidney disease, hepatitis B and antiviral treatments	27
	27
Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis	27
Hepatobiliary disease after bone marrow transplant: A cross‐sectional study of 377 patients	27
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection	27
CAMP‐B score predicts the risk of hepatocellular carcinoma in patients with chronic hepatitis B after HBsAg seroclearance	27
Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences	27
Issue Information	26
Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras	26
Letter: Clinical Trial Design Considerations for Hospitalised Patients With Ulcerative Colitis Flares and Application to Study Hyperbaric Oxygen Therapy in the NIDDK HBOT‐UC Cons	26
Editorial: Decoding ACLF—Sub‐Phenotyping to Advance Precision Medicine in Acute‐On‐Chronic Liver Failure	26
Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease	26
Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma	26
Letter: COVID‐19 outcomes and anti‐TNF treatments—comprehensive evidence matters	26
Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV‐Infected HCC Patients Undergoing Immunotherapy	26
Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor	26
Editorial: When and What to Ask—Capturing the Symptoms Experienced by Patients With PSC	25
Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment	25
Editorial: Clinical Impact of Lipid Profile Change After DAA Treatment in CHC Patients—Authors' Reply	25
	25
Machine learning liver histology scores correlate with portal hypertension assessments in nonalcoholic steatohepatitis cirrhosis	25
Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'	25
Research Communication: Healthcare Utilisation Patterns in Patients With Irritable Bowel Syndrome Across an Integrated Healthcare System	25
Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply	25
Letter: Albumin—Does formulation matter?	25
Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply	25
Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologi	25
Trends in the prevalence rates and predictive factors of coeliac disease: A long‐term nationwide follow‐up study	25
Maladaptive weight control and eating behaviours in female adolescents/young adults are associated with increased risk of irritable bowel syndrome in adulthood: Results from the Growing Up Today Study	24
Trends in aetiology‐based hospitalisation for cirrhosis before and during the COVID‐19 pandemic in the United States	24
Systematic review: The use of large language models as medical chatbots in digestive diseases	24
Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas	24
Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha‐2‐Delta Ligand PD‐217,014 in Patients With Irritable Bowel Syndrome	24
Randomised clinical trial: Design of the SYNERGY‐NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction‐associated steatohepatitis and modification of screening strategy	24
Clinical Trial: Evaluating a Single 1600 mg Tablet Regimen of 5‐Aminosalicylate for Ulcerative Colitis—The EASI Trial	24
Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series	24
Letter: the diagnostic value of ultrasound‐based versus CT‐based sarcopenia measurement in cirrhosis	24
Editorial: Rebuilding Rome—Revising Diagnostic Criteria for Irritable Bowel Syndrome	24
The impact of red blood cell transfusion practices on inpatient mortality in variceal and non‐variceal gastrointestinal bleeding patients: a 20‐year US nationwide retrospective analysis	24
Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom	24
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs	23
Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States	23
	23
Systematic review: Clinical phenotypes, histopathological features and prognosis of enteropathy due to angiotensin II receptor blockers	23
Editorial: Variceal Bleeding in Patients Receiving Atezolizumab–Bevacizumab for Hepatocellular Carcinoma—Don't Ignore the Risk Factors! Authors' Reply	23
Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?	23
Autoimmune hepatitis and metabolic syndrome‐associated disease development: a U.S. cohort study	23
Low liver fat in non‐alcoholic steatohepatitis‐related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality	23
Review article: current and emerging therapies for acute alcohol‐associated hepatitis	23
Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound	23
	22
Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition?	22
Association of High‐Sensitivity Troponins in Metabolic Dysfunction‐Associated Steatotic Liver Disease With All‐Cause and Cause‐Specific Mortality	22

Natural history and impact of irritable bowel syndrome‐type symptoms in inflammatory bowel disease during 6 years of longitudinal follow‐up	22
Issue Information	22
Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland	22
Editorial: Endomysial Antibodies for a No‐Biopsy Diagnosis of Coeliac Disease—The Jury Is Still Out	22
	22
	22
	22
Letter on ‘Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma’	22
Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns	22
Real‐Time Assessment of H. pylori Infection to Guide Molecular Antibiotic Resistance Testing: A Combined Endoscopy‐Gastric Juice Analysis Approach	21
Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes	21
Racial and ethnic differences in diet quality and food insecurity among adults with fatty liver and significant fibrosis: a U.S. population‐based study	21
Novel microbiome signatures for non‐invasive diagnosis of adenoma recurrence after colonoscopic polypectomy	21
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH	21
IL23 Receptor Polymorphism Is a Predictor of Anti‐Tumour Necrosis Factor‐α‐Induced Paradoxical Psoriasis in Inflammatory Bowel Disease	21
Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply	21
Effect of time to pre‐emptive transjugular intrahepatic portosystemic shunt on patient outcome, a UK multicentre cohort study	21
Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply	21
Editorial: DoesESWL‐ERCPfor pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis?	20
Letter: Safety after cessation of nucleos(t)ide analogue therapy in patients with chronic hepatitis B infection—Authors' reply	20
Editorial: The use of Baveno VI and VII criteria in patients with hepatocellular carcinoma	20
Editorial: group‐based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome—authors' reply	20
Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States	20
Letter: efficacy of peppermint oil in irritable bowel syndrome	20
Editorial: Viral hepatitis elimination: Still a big challenge: Care is not only for C	20
Editorial: One step closer to personalised nutrition therapy for irritable bowel syndrome	20
Editorial: lack of gastrointestinal symptoms caused by gluten in patients without coeliac disease—time to ditch the ‘gluten’ from ‘non‐coeliac gluten sensitivity’	20
Letter: Shifting focus—From ChatGPT to specialised medical LLMs	20
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome	20
Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply	20
Editorial: PPIs and gastric cancer – Are we dealing with a carcinogen? Authors' reply	20
Letter: Should ulcerative colitis be monitored more or less invasively?	20
Letter: efficacy of peppermint oil in irritable bowel syndrome—authors' reply	19
	19
Systematic Review: Ultrasound Goes Echo—Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound	19
Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply	19
Editorial: improving the use of Montreal classification through a bidirectional approach	19
Review article: A practical approach to persistent gastrointestinal symptoms in inflammatory bowel disease in remission	19
Type 1 diabetes and microscopic colitis: A nationwide matched case–control study in Sweden	19
Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions	19
Editorial: potassium‐competitive acid blockers—is there a role for more complete acid suppression?	19
Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease	19
Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study	19
Early serum ammonia variation in critically ill patients with cirrhosis: A multicentre cohort study	19
Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study	19
Editorial: implications and future perspectives of the increase in biologics use in paediatric inflammatory bowel disease	19
Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—Implications for stopping rules and the HBV<	19
Real‐world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti‐TNF agent	18
Treatment of inflammatory bowel disease with steroid‐sparing medications is age‐dependent – Results from a Danish nationwide cohort study, 2000–2018	18
Incidence, outcomes, and impact of COVID‐19 on inflammatory bowel disease: propensity matched research network analysis	18
Burden of Invasive Fungal Diseases in Patients With Alcohol‐Related Hepatitis and Organ Failure	18
	18
Age at treatment initiation predicts response in children with chronic hepatitis B	18
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis	18
Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone	18
Risk of colorectal neoplasia according to histologic disease activity in patients with inflammatory bowel disease and colonic post‐inflammatory polyps	18
Systematic review with meta‐analysis: artificial intelligence in the diagnosis of oesophageal diseases	18
Review article: Faecal biomarkers for assessing small intestinal damage in coeliac disease and environmental enteropathy	18
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites	18
Increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis with concurrent fatty liver	18
Editorial: When Yeast Turns Beast—Unmasking an Overlooked Threat in Alcohol‐Related Hepatitis	18
Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply	17
Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study	17
Editorial: evolution of GLP‐1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity – authors’ reply	17
Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply	17
Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study	17
Dietary factors and patterns in relation to risk of later‐onset ulcerative colitis in Chinese: A prospective study of 0.5 million people	17
Letter: predictive role of magnetic resonance elastography in chronic liver disease – still a long way to go	17
Editorial: The use of Baveno VI and VII criteria for portal hypertension and varices in patients with hepatocellular carcinoma—Authors' reply	17
Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients—authors' reply	17
Timely Follow‐Up After a First Diagnosis of Cirrhosis is Associated With Reduced Mortality but No Impact on Rehospitalisations: A Population‐Based Cohort of 8852 Patients	17
Editorial: optimising hepatitis B vaccine response in inflammatory bowel disease—time to get some skin in the game. Authors' reply	17
Editorial: colorectal cancer in elderly‐onset inflammatory bowel disease—what is the risk?	16
Letter: fighting the battle but losing the war—inflammatory bowel disease and venous thromboembolism. Authors' reply	16
Editorial: COVID‐19 vaccines are safe and effective in patients with inflammatory bowel disease—but many unanswered questions remain	16
Editorial: the burden of alcohol‐related liver disease emergency admissions in England may be twice as high as previously thought—authorsʼ reply	16
Epidemiology and risk factors for histopathologic characteristics of non‐alcoholic fatty liver disease in South America	16
Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply	16
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!	16
Editorial: immunosuppression and SARS‐CoV‐2 vaccination—where do we stand?	16
Editorial: predictors of disease activity during pregnancy in women with inflammatory bowel disease—a Danish cohort study	16
Editorial: ‘Risk‐Adapted Starting Ages of Colorectal Cancer Screening for People With Diabetes or Metabolic Syndrome’	16
Editorial: coeliac disease follow‐up guided by gluten immunogenic peptides—are we there yet?	16
Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors’ reply	16
Letter: Low to moderate alcohol intake and progression of non‐alcoholic fatty liver disease	16
Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply	16
Editorial: Time to address quality of life in our IBD treatment—IBD nurse intervention as a key part of multimodal IBD management	16
Editorial: Faecal microbiota transplantation inIBS—Moving closer or away from success? Authors' reply	16
Letter on “Association Between Viral Replication Activity and Postoperative Recurrence of HBV‐Related Hepatocellular Carcinoma”–Authors' Reply	16
Letter: 5‐aminosalicylate maintenance treatment in mild Crohn's disease	16
Editorial: the other bug	16
Quantitative MRCP and metrics of bile duct disease over time in patients with primary sclerosing cholangitis: A prospective study	15
Editorial: bacterial gut symbionts as live biotherapeutic agents in IBS—a rosy future despite potential long‐term safety concerns. Authorsʼ reply	15
Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome	15
Socio‐economic association of alcohol use disorder and cardiovascular and alcohol‐associated liver disease from 2010 to 2019	15